Open Label, Randomized, Cross-over Study to Explore the Pharmacokinetics of BAY1834845 After Oral and Intravenous Dosing, Including Food Effect and Absolute Bioavailability (Part A), and to Investigate the Effect of BAY1834845 on the Pharmacokinetics of Orally Administered Methotrexate (Part B) in Healthy Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2018
At a glance
- Drugs BAY 1834845 (Primary) ; BAY 1834845 (Primary) ; Methotrexate
- Indications Pelvic inflammatory disorders
- Focus Pharmacokinetics
- Sponsors Bayer
- 12 Jan 2018 Planned primary completion date changed from 6 Dec 2017 to 22 Jan 2018.
- 12 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2017 Planned End Date changed from 31 Jan 2018 to 28 Feb 2018.